Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as wel...Show More
competitor of
Metrics
marketSTOCKS
msh_idCOM:CANDELTX
localeus
websitehttps://www.candeltx.com/
ipo_date2021-07-27
primary_stock_msh_idNASDAQ:CADL
source_refba52062a-0aa2-4cf3-9609-e8483e492fc4
products_or_servicesViral immunotherapies for cancer treatment